[1] Bunazosin was initially developed to treat benign prostatic hyperplasia (BPH).

It has been approved in Japan in a topical form to treat glaucoma.

The mechanism of action is a reduction of aqueous outflow through the uveoscleral pathway resulting in lowering the intraocular pressure.

Systemic Alpha-1 adrenergic receptor antagonists have been implicated in Intraoperative Floppy Iris Syndrome (IFIS).

Bunazosin potentially could have the same effect but there has been no research to substantiate this as a risk for cataract surgery.